Farydak (panobinostat); Novartis; For the treatment of multiple myeloma, Approved February 2015


Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015


Lenvima (lenvatinib); Eisai; For the treatment of thyroid cancer, Approved February 2015


Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of metastatic squamous non-small cell lung cancer, Approved March 2015


Unituxin (dinutuximab); United Therapeutics; For the treatment of pediatrics with high-risk neuroblastoma, Approved March 2015


The article was refered to: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology